These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36732646)

  • 1. Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study.
    Fu R; Huang J; Tian X; Liang C; Xiong Y; Zhang JT; Jiang B; Dong S; Gong Y; Gao W; Li F; Shi Y; Liu Z; Gao X; Chen R; Zhong W; Zhang Y
    Mol Oncol; 2023 May; 17(5):825-838. PubMed ID: 36732646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
    Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
    Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
    Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
    Tan AC; Lai GGY; Saw SPL; Chua KLM; Takano A; Ong BH; Koh TPT; Jain A; Tan WL; Ng QS; Kanesvaran R; Rajasekaran T; Kalashnikova E; Renner D; Sudhaman S; Malhotra M; Sethi H; Liu MC; Aleshin A; Lim WT; Tan EH; Skanderup AJ; Ang MK; Tan DSW
    Cancer; 2024 May; 130(10):1758-1765. PubMed ID: 38422026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
    Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
    J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer.
    Tian X; Liu X; Wang K; Wang R; Li Y; Qian K; Wang T; Zhao X; Liu L; Zhang PL; Xiong Y; Rui J; Chen R; Zhang Y
    Thorac Cancer; 2024 Apr; 15(10):797-807. PubMed ID: 38409945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
    Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
    Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
    J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
    Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
    Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.
    Wang B; Pei J; Wang S; Cheng K; Yu J; Liu J
    Crit Rev Oncol Hematol; 2022 Sep; 177():103771. PubMed ID: 35905822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.
    Qiu B; Guo W; Zhang F; Lv F; Ji Y; Peng Y; Chen X; Bao H; Xu Y; Shao Y; Tan F; Xue Q; Gao S; He J
    Nat Commun; 2021 Nov; 12(1):6770. PubMed ID: 34799585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
    Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
    Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
    Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
    Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 17. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
    Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer.
    Abbosh C; Hodgson D; Doherty GJ; Gale D; Black JRM; Horn L; Reis-Filho JS; Swanton C
    Trends Cancer; 2024 Jul; 10(7):643-654. PubMed ID: 38839544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.
    Lee JS; Han Y; Yun WG; Kwon W; Kim H; Jeong H; Seo MS; Park Y; Cho SI; Kim H; Kim JY; Seong MW; Jang JY; Park SS
    Clin Chem; 2022 Dec; 68(12):1509-1518. PubMed ID: 36177751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.